Abstract
Introduction: Community-acquired urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli have limited oral therapeutic options and pose significant clinical challenges. The goal of this study was to evaluate the in vitro synergy between CFM and AMC against ESBL E. coli with aims to identify an oral treatment option for UTIs. Methods: Minimum inhibitory concentrations (MICs) of CFM in the presence of AMC were determined for 46 clinical isolates by placing a CFM Etest on a plate with AMC impregnated in the agar. Isolates with CFM MIC ≤1 μg/mL in the presence of AMC were considered susceptible to the CFM and AMC combination. Five isolates were then selected for further testing using time-kill analysis in the presence of CFM, AMC, and CFM with AMC. Time-kill curves were plotted to determine synergy over 24 h. Results: AMC improved the activity of CFM against ESBL E. coli isolates by 128-fold in the Etest analysis with 85% of tested isolates being susceptible to the combination. A fourfold or greater reduction in CFM MIC was exhibited in 44 of 46 (96%) isolates when in the presence of AMC. Synergy and bactericidal activity between CFM and AMC were exhibited in each of the five isolates tested by time-kill analysis. Discussion/Conclusion: This study found that AMC improves the activity of CFM against ESBL E. coli and that this antibiotic combination has potential as an oral therapeutic option to treat ESBL E. coli UTIs.
References
1.
Cohen Stuart
J
, Leverstein-Van Hall
M
, Kortmann
W
, Verlind
J
, Mulder
F
, Scharringa
J
, Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series
. Eur J Clin Microbiol Infect Dis
. 2018 Oct
;37
(10
):2021
–5
.2.
Prakash
V
, Lewis
JS
, Herrera
ML
, Wickes
BL
, Jorgensen
JH
. Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases
. Antimicrob Agents Chemother
. 2009 Mar 1
;53
(3
):1278
–80
. .3.
Stewart
AG
, Harris
PNA
, Henderson
A
, Schembri
MA
, Paterson
DL
. Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections
. J Antimicrob Chemother
. 2020 Sep 1
;75
(9
):2384
–93
. .4.
Rodríguez-Baño
J
, Navarro
MD
, Romero
L
, Martínez-Martínez
L
, Muniain
MA
, Perea
EJ
, Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing escherichia coli in nonhospitalized patients
. J Clin Microbiol
. 2004 Mar 1
;42
(3
):1089
–94
.5.
Campbell
JD
, Lewis
JS
, McElmeel
ML
, Fulcher
LC
, Jorgensen
JH
. Detection of favorable oral cephalosporin-clavulanate interactions by in vitro disk approximation susceptibility testing of extended-spectrum-beta-lactamase-producing members of the enterobacteriaceae
. J Clin Microbiol
. 2012 Mar
;50
(3
):1023
–6
. .6.
Bingen
E
, Bidet
P
, Birgy
A
, Sobral
E
, Mariani
P
, Cohen
R
. In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection
. J Clin Microbiol
. 2012 Jul 1
;50
(7
):2540
–1
. .7.
Livermore
DM
, Hope
R
, Mushtaq
S
, Warner
M
. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers
. Clin Microbiol Infect
. 2008 Jan
;14
(Suppl 1
):189
–93
. .8.
Abdelraouf
K
, Stainton
SM
, Nicolau
DP
. In vivo pharmacodynamic profile of ceftibuten-clavulanate combination against extended-spectrum-β-lactamase-producing enterobacteriaceae in the murine thigh infection model
. Antimicrob Agents Chemother
. 2019 May 6
;63
(7
):e00145
–19
. .9.
Rossi
B
, Soubirou
JF
, Chau
F
, Massias
L
, Dion
S
, Lepeule
R
, Cefotaxime and amoxicillin-clavulanate synergism against extended-spectrum-β-lactamase-producing Escherichia coli in a murine model of urinary tract infection
. Antimicrob Agents Chemother
. 2016 Jan
;60
(1
):424
–30
.10.
Teva Pharmaceuticals USA. Inc. Cefdinir for Oral Suspension (Package Insert). North Wales, PA; 2018.
11.
Aurobindo Pharma Limited. Cefpodoxime Proxetil (Package Insert). NJ: East Windsor; 2018.
12.
Ascend Laboratories, LLC. Cefixime (Package Insert). NJ: Parsippany; 2018.
13.
Tamma
PD
, Aitken
SL
, Bonomo
RA
, Mathers
AJ
, van Duin
D
, Clancy
CJ
. Infectious diseases society of America antimicrobial resistant treatment guidance: gram-negative bacterial infections
. Clin Infect Dis
. 2020
.14.
Dallenne
C
, Da Costa
A
, Decré
D
, Favier
C
, Arlet
G
. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae
. J Antimicrob Chemother
. 2010 Mar
;65
(3
):490
–5
. .15.
Clinical and laboratory standards institute (CLSI)
. CLSI supplement M100
. In: Performance standards for antimicrobial susceptibility testing
. 32nd ed. Wayne, PA 19087 USA
: Clinical and Laboratory Standards Institute
; 2022
.16.
BioMerieux Inc. ETEST. Marcy-l’Étoile, France: BioMerieux; 2012.
17.
Micro Labs USA Inc
. Amoxicillin and Clavulanate Potassium (Package Insert)
. NJ
: Basking Ridge
; 2020
.18.
Pillai
S
, Moellering
R
, Eliopolous
G
. Antimicrobial Combinations
. In: Lorian
V
, editor. Antibiotitics in Laboratory Medicine
. 5th ed. Philadelphia, PA
: Lippincott, Williams, and Wilkins
; 2005
. p. 365
–438
.19.
Guay
DR
. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin
. Pediatr Infect Dis J
. 2000 Dec
;19
(12
):S141
. .20.
Klepser
ME
, Marangos
MN
, Patel
KB
, Nicolau
DP
, Quintiliani
R
, Nightingale
CH
. Clinical pharmacokinetics of newer cephalosporins
. Clin Pharmacokinet
. 1995 May
;28
(5
):361
–84
. .21.
Lagace-Wiens
PRS
. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum- -lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate
. J Antimicrob Chemother
. 2006 Apr 4
;57
(6
):1262
–3
.22.
Sanofi-Aventis Canada Inc
. Suprax (Product Monograph)
. Quebec
: Laval
; 2016
.23.
Beytur
A
, Yakupogullari
Y
, Oguz
F
, Otlu
B
, Kaysadu
H
. Oral amoxicillin-clavulanic Acid treatment in urinary tract infections caused by extended-spectrum beta-lactamase-producing organisms
. Jundishapur J Microbiol
. 2014 Dec 6
;8
(1
):e13792
. .24.
Critchley
IA
, Cotroneo
N
, Pucci
MJ
, Mendes
R
. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017
. PLoS One
. 2019 Dec 10
;14
(12
):e0220265
.25.
Foxman
B
. The epidemiology of urinary tract infection
. Nat Rev Urol
. 2010 Dec
;7
(12
):653
–60
. .26.
Schappert
SM
, Rechtsteiner
EA
. Ambulatory medical care utilization estimates for 2007
. Vital Health Stat 13
. 2011
;(169
):1
–38
. (Number 159).27.
Tamma
PD
, Humphries
RM
. PRO: testing for ESBL production is necessary for ceftriaxone-non-susceptible Enterobacterales: perfect should not be the enemy of progress
. JAC Antimicrob Resist
. 2021
;3
(2
):dlab019
. .28.
Mathers
AJ
, Lewis
JS
II. CON: Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales
. JAC Antimicrob Resist
. 2021
;3
(2
):dlab020
. .29.
Flores-Mireles
AL
, Walker
JN
, Caparon
M
, Hultgren
SJ
. Urinary tract infections: epidemiology, mechanisms of infection and treatment options
. Nat Rev Microbiol
. 2015 May
;13
(5
):269
–84
. .30.
Lob
SH
, Nicolle
LE
, Hoban
DJ
, Kazmierczak
KM
, Badal
RE
, Sahm
DF
. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014
. Diagn Microbiol Infect Dis
. 2016 Aug
;85
(4
):459
–65
. .31.
Jernigan
JA
, Hatfield
KM
, Wolford
H
, Nelson
RE
, Olubajo
B
, Reddy
SC
, Multidrug-resistant bacterial infections in U.S. Hospitalized patients, 2012–2017
. N Engl J Med
. 2020 Apr 2
;382
(14
):1309
–19
.32.
Al-Tamimi
M
, Abu-Raideh
J
, Albalawi
H
, Shalabi
M
, Saleh
S
. Effective oral combination treatment for extended-spectrum beta-lactamase-producing Escherichia coli
. Microb Drug Resist
. 2019 Oct 1
;25
(8
):1132
–41
. .33.
Nordmann
P
, Poirel
L
. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria
. Clin Infect Dis
. 2019 Nov 13
;69
(Suppl 7
):S521
–8
. .© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
